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Abstract
Background: The Werner protein (WRNp), a member of the RecQ helicase family, is strongly associated with the nucleolus,
as is nucleolin (NCL), an important nucleolar constituent protein. Both WRNp and NCL respond to the effects of DNA
damaging agents. Therefore, we have investigated if these nuclear proteins interact and if this interaction has a possible
functional significance in DNA damage repair.
Methodology/Principal Findings: Here we report that WRNp interacts with the RNA-binding protein, NCL, based on
immunoprecipitation, immunofluorescent co-localization in live and fixed cells, and direct binding of purified WRNp to
nucleolin. We also map the binding region to the C-terminal domains of both proteins. Furthermore, treatment of U2OS
cells with 15 mM of the Topoisomerase I inhibitor, camptothecin, causes the dissociation of the nucleolin-Werner complex in
the nucleolus, followed by partial re-association in the nucleoplasm. Other DNA damaging agents, such as hydroxyurea,
Mitomycin C, and aphidicolin do not have these effects. Nucleolin or its C-terminal fragment affected the helicase, but not
the exonuclease activity of WRNp, by inhibiting WRN unwinding of G4 tetraplex DNA structures, as seen in activity assays
and electrophoretic mobility shift assays (EMSA).
Conclusions/Significance: These data suggest that nucleolin may regulate G4 DNA unwinding by WRNp, possibly in
response to certain DNA damaging agents. We postulate that the NCL-WRNp complex may contain an inactive form of
WRNp, which is released from the nucleolus upon DNA damage. Then, when required, WRNp is released from inhibition and
can participate in the DNA repair processes.
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Introduction
The nucleolus is a nuclear domain long known to play a central
role in ribosome biogenesis and RNA metabolism [1,2,3]. A key
nucleolar protein is nucleolin, a RNA binding phosphoprotein [4],
that plays a major role in nucleolar organization and function,
especially ribosome genesis [5]. Nucleolin is found not only in the
nucleolus, but also in the nucleus, cytoplasm and cell surface [6,7].
It has recently become apparent that the nucleolus has other
crucial functions beyond RNA genesis and manipulation [8].
Indeed, recent proteomic analyses of the nucleolus have shown
that there are well over 500 nucleolar proteins, of which 12% are
unconnected to nucleic acid metabolism or processing and over
30% are novel proteins of unknown function [9,10,11].
Recently, a new function of nucleolin has emerged, as a
responder to cellular stress. Nucleolin rapidly translocates from the
nucleolus to the nucleoplasm in response to heat shock [12,13],
can increase its RNA binding activity in response to UV and
ionizing radiation [14], and can inhibit Nucleotide Excision
Repair [15].
Nucleolin is an emerging stress response protein that also has
homologous strand pairing activity and interacts with a number of
DNA recombination complexes that are involved in homologous
recombinational repair [12,14,16]. For example, nucleolin inter-
acts with Replication Protein A (RPA) and the tumor suppressor
p 53. While RPA binds single stranded DNA, p 53 regulates the
DNA strand-transferase activity of Rad51 [17,18]. Recent reports
indicate that both nucleolin and WRN bind to Rad51 [16,18]. It is
thus likely that nucleolin participates in and modulates homolo-
gous recombinational repair of DNA.
Werner Syndrome protein, WRNp, is a major stress-response
protein associated with human nucleoli. Werner syndrome (WS) is
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premature onset of aging symptoms and a higher incidence of
cancer [19]. The WRN gene product is a 160 kDa protein of the
RecQ DNA helicase family [20], a family of proteins involved in
maintaining genomic stability [21]. Werner protein (WRNp)
exhibits three enzymatic activities: 39 to 59 RNA and DNA
helicase, ATPase, and exonuclease [22,23,24,25]. WRNp has a
nuclear localization signal (NLS) near the C-terminus of the
protein and has been detected in both the nucleoplasm and
nucleolus [26,27]. A nucleolar targeting sequence has been found
in WRNp [28]. The WRN protein forms functional complexes
with several cellular proteins, some of which stimulate its helicase
activity, such as RPA [29,30] and TRF2 [31]. Nucleolin and
Werner protein exhibit dynamic trafficking from the nucleolus to
nuclear foci in response to DNA damage. We sought to determine
if there is a physical interaction between nucleolin and WRNp and
what would be the functional significance of this interaction in the
context of nucleolar biology and nuclear trafficking of nucleolin
and WRNp.
Materials and Methods
Proteins, Antibodies, Oligonucleotides and Cell Lines
The cloning and expression of GST-tagged WRN fragments,
His6-WRN and full-length WRN has been described previously
[30,32]. GST tagged DN-NCL and Nucleolin fragments used were
described by us [14]. RFP-WRN [33] was a kind gift of Dr. Marek
Rusin, Maria Sklodowska-Curie Memorial Institute, Gliwice,
Poland; GFP-NCL constructs are described below.
The following antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA): Rabbit anti-GST, rabbit anti-
GFP mouse monoclonal anti-nucleolin (C23) antibody (MS-3),
rabbit anti-nucleolin (H250), rabbit anti-WRN (H-300). Additional
antibodies purchased were mouse monoclonal anti-nucleolus
(Calbiochem, San Diego, CA), mouse monoclonal anti-nucleolin
(MBL), rabbit anti-WRN1 (Novus, Littleton, CO), mouse anti-
WRNp mAb (BD Transduction Laboratories, San Diego, CA).
Horseradish peroxidase-, Cy2 and Cy3-conjugated secondary
mAbs were purchased from Jackson Immunoresearch Laborato-
ries (West Grove, PA). Alexa 488-conjugated secondary mAbs and
the DNA stain 49,6-diamidino-2-phenylindole dihydrochloride
(DAPI) were purchased from Molecular Probes (Eugene, OR).
Normal rabbit or mouse IgG (Sigma or Santa Cruz) was used as a
negative control.
TERT-1604 (telomerase-immortalized normal fibroblasts were
generously provided by Dr. Jerry W. Shay), HeLa, Saos-2,
MO59K, MO59J and U2OS were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomy-
cin, 1% vitamins and 1% amino acids (BRL-GIBCO Life
Technologies, Inc). The SV40-transformed normal human cell
line, GM00637D fibroblasts, WRN
2/2 transformed human
AG11395 fibroblasts, human primary fibroblast MRC-5 and
WRN
2/2 primary fibroblast AG03141C (all from Coriell Cell
Repositories) were grown in minimum essential medium supple-
mented as above.
Oligonucleotides used to produce tetraplex DNA were pur-
chased from The Midland Certified Reagent Company, Inc
(Midland, Texas, USA). Radioactively labeled [c32-P]dATP was
purchased from Amersham.
Immunoprecipition, SDS-PAGE and Immunoblot
Nuclear extracts of TERT-1604 or HeLa cells were prepared as
described previously [34]. Whole cell extracts (WCE) were
prepared with 5610
6 cells for each experimental point. The cells
were washed with PBS and incubated with lysis buffer containing
150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.5% NP-40 and
proteinase inhibitor cocktail at 4uC for 30 min. The WCE were
then centrifuged at 14,0006g for 20 min. Supernatants were
collected and processed for immunoprecipitation, immunoblotting
and detection as described previously [35].
Care was taken to minimize the presence of nucleic acids in
lysates, nuclear extracts and purified proteins. We employed salt
concentration, DNA binding columns and addition of nuclease in
order to reduce nucleic acid concentration to below detectable
levels, as judged by absorbance.
In Vitro Binding
ELISA assays were performed exactly as described in Indig et
al., 2004, with purified WRN, GST-DN-NCL and GST-nucleolin
fragments at 100 ng/ml. Experiments were repeated at least six
times.
In vitro pull down assay was performed basically as described in
[31,36]. GST-WRN fragments were incubated with TERT-1604
or HeLa nuclear extract, while GST-nucleolin fragments were
incubated with His6-WRN (approximately 1 mg each). Reactions
were then immunoprecipitated with anti-GST, separated on 4–
15% polyacrylamide gels and immunoblotted as described above.
The resulting signal was visualized by chemiluminiscence (ECL
Plus, Amersham Biosciences). Experiments were repeated at least
three times.
GFP-NCL Constructs and Immunoprecipitation
The full-length human nucleolin and the fragments containing
amino acids 1 to 283 and 284 to 707 were cloned by PCR into the
pEGFP-C3 vector (Clontech) at the Xho1/BamH1 sites. The
plasmids were transiently transfected with Fugene HD at a 4:1
ratio in 80% confluent HeLa cells. The next day, transfection
efficiency was verified by fluorescence microscopy and the cells
were harvested in cold PBS. Proteins were extracted in lysis buffer
(150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.5% NP-40) and
proteases inhibitor cocktail (Roche)) at 4uC for 30 min, centrifuged
at 14000 xg for 20 min at 4uC. The supernatant was used for
immunoprecipitation.
Immunoprecipitation was performed as described before [34].
Briefly, 2 mg of protein extracts were incubated at 4uC with WRN
antibody for 1 h. Protein G coated magnetic beads were then
added and the reaction was allowed to proceed over night at 4uC.
The proteins were then washed in lysis buffer and twice in cold
PBS before being eluted and loaded on SDS-PAGE. Western blot
was performed with GFP Ab (Santa Cruz).
DNA Damage Treatment, Indirect Immunofluorescence
and Microscopy
Cells were grown on cover slips or CC2-coated slide flasks
(Nunc Nalge) for 24 h and then incubated with the following DNA
damaging agents for the indicated time period: Mitomycin C
(0.1 mg/ml for 12 h), H2O2 250 mM for 30 min, hydroxyurea
100 mm for 16 h, bleomycin 2.5 mg/ml for 2 h, 4NQO (0.1 mg/ml
for 12 h) and CPT 15 mM for 12 h. Coverslips were processed for
indirect immunofluorescence as described previously [34], except
that those examined by confocal microscopy were incubated with
primary antibodies for 16 h at 4uC, and secondary antibody
conjugated with fluorescence dye for 1 h at room temperature.
After washing three times (10 min each), the coverslips were
mounted in Vectashield (Vector Laboratories) and viewed under a
laser scanning confocal microscope (Zeiss 410) in separate
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overlaid and analyzed with Metamorph imaging system 4.1
(Universal Imaging Corp.). Experiments were repeated at least
three times. Approximately 30 cells were analyzed for each
treatment.
Co-Transfection and Live Cell Microscopy
U2OS cells (50 K) were plated onto MatTek dishes. After
overnight growth, sub-confluent cells were transfected in serum-
free medium using the Fugene 6 (Roche) reagent according to
manufacturer’s instructions. The following ratio produced the best
results:mg GFP-NCL:mg RFP-WRN:ml Fugene 6 1:1.5:18. Cells
were imaged 40–66 hours post-transfection with a Zeiss 710
confocal equipped with a temperature-controlled and humidified
CO2 chamber and with a definite focus system. Time series (2–12
hours) were obtained from cells treated with either 1 or 15 mM
CPT by scanning every 30–120 seconds. Still images or movies
were obtained from these series using the Zeiss Zen software.
Experiments were repeated at least three times.
Exonuclease Assay
Exonuclease assay reaction mixtures (10 ml) contained 40 mM
Tris (pH 7.4), 5 mM MgCl2, 1 mM dithiothreitol, 0.1 mg/ml
BSA, 1 mM ATP, and WRNp full-length recombinant protein
(16 nM) in the presence or absence of DN-NCL. The amount of
the double-stranded exonuclease substrate in the reaction mixture
was approximately 3 fmol. Reactions were initiated by the
addition of WRN protein and incubated at 37uC for 60 min.
Reactions were stopped by the addition of an equal volume of
formamide loading buffer (80% formamide, 0.56Tris-borate
EDTA, 0.1% bromphenol blue, and 0.1% xylene cyanol). The
digestion products of these reactions were separated on 15%
denaturing polyacrylamide gels, visualized using a PhosphorIma-
ger (Molecular Dynamics), and quantitated using ImageQuant
software (Molecular Dynamics). Experiments were repeated at
least three times.
WRN Helicase Assay
A 34 bp forked duplex oligonucleotide [37] was used to assay
WRN helicase activity in the presence of DN-NCL and nucleolin
fragments.
Proteins and radiolabeled DNA substrates were incubated in
helicase reaction buffer (50 mM Tris-HCl pH 7.5, 4 mM MgCl2,
2 mM ATP, 2 mM DTT and 0.1 mg/ml BSA) in a final volume
of 20 ml. Reactions were incubated at 37uC for 20 min, then
terminated by the addition of 3X stop dye (0.05 M EDTA, 40%
Glycerol, 1% SDS, 0.05% bromophenol blue, and 0.05% xylene
cyanol) to a final concentration of 1X. Products were resolved on a
12% native polyacrylamide gel, visualized using a PhosphoImager
and quantitated using Image-Quant software (Molecular Dynam-
ics, Palo Alto, CA). The percentage of single-stranded substrate
produced by helicase activity was calculated with the following
formula:
% Single-stranded=1006P/(S+P).
Where P is the product, and S is the substrate. The values for P
and S have been corrected after subtracting the background values
in the no enzyme control. Experiments were repeated at least five
times.
UvrD Helicase Assay
The helicase reaction contained 0.5 nM
32P-end labeled forked
DNA duplex and the indicated concentration of proteins in
50 mM Tris-HCl pH 7.5, 4 mM MgCl2, 2 mM ATP,
2 mM DTT, and 0.1 mg/ml BSA. The reactions were initiated
by addition of 10 fmol UvrD protein [38]. Reactions were
analyzed as above. The percentage of single-stranded substrate
was calculated using the same formula as in WRN helicase assay.
Experiments were repeated at least three times.
G4 Tetraplex Unwinding
G4 DNA was prepared essentially as described by Sen and
Gilbert [39], but omitting the potassium salt during folding.
The G4 DNA unwinding assay was performed essentially as
described by Huber and co-workers, [40]. We used the 39-mer
OX1-T DNA (Oxytricha sp. telomeric) or the 49-mer TP-G4
DNA with similar results. Experiments were repeated at least six
times. Phosphorimager images were contrast-enhanced using
Adobe Photoshop.
G4 Tetraplex Electrophoretic Mobility-Shift Assay (EMSA)
DNA-protein binding was assessed using EMSA, essentially as
described in [36] and [31]. Experiments were repeated at least
three times. Phosphorimager images were contrast-enhanced using
Adobe Photoshop.
Results
Werner Helicase and Nucleolin Co-Precipitate
Anti-WRN and anti-NCL antibodies reciprocally co-immuno-
precipitate the two proteins from nuclear extracts of TERT-1604
cells (Figure 1). Similar results were obtained with other anti-NCL
and anti-WRN antibodies (Figure S1A). Thus, WRNp (160 kDa)
and NCL (100 kDa) are present in the same protein complex
immunoprecipitated from nuclear extracts of TERT-1604 cells.
The amount of co-precipitating NCL and WRN is only a fraction
of the total amount of these proteins present in the extracts, as seen
in Figure 1. This is unsurprising, as both NCL and WRN are
multi-functional proteins that participate in several different
protein complexes at the same time, and thus, only a fraction of
each protein is present in each complex. When we immunopre-
cipitated WRNp with rabbit anti-WRN from cell extracts of six
other cell lines (Figure S1B), NCL was detected in all precipitates.
Both proteins were absent from anti-WRN precipitates of extracts
from a WS cell line, Ag11395, producing a mutant WRN protein
truncated at a.a. 369 [27], which is not precipitated by the anti-
WRN.
In Vitro Binding of WRNp and NCL and Mapping of the
Interaction to the C-Termini of Both Proteins
In order to verify the protein-protein interaction between
WRNp and NCL that was indicated by the immunoprecipitation
experiments, we conducted in vitro binding experiments using
purified proteins (Figure 2). ELISA plates were coated with WRNp
or various GST-NCL fragments (see Figure 2D). Purified WRNp
preferentially bound to the immobilized RGG fragment of NCL in
ELISA immunoassays (Figure 2A). When immobilized WRN
protein was incubated with GST-NCL fragments, the RGG
fragment was found to bind WRNp to a greater extent than the
other NCL fragments (Figure 2B).
In order to map the reciprocal binding regions of NCL and
WRN, we performed GST pull-down experiments. Utilizing eight
GST-fused WRN fragments (Figure 2C) mixed with nuclear
extract, we found that only two WRN fragments pulled down
NCL: the HRDC+(WRN residues 1072–1432) and C-terminal
(WRN residues 949–1432) fragments. As neither the RQC
fragment (WRN residues 949–1092), nor the RQC+fragment
(WRN residues 949–1236) pulled-down NCL, this result indicates
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binding. Thus, the likely NCL-interacting region of WRNp maps
to WRN residues 1236–1432, which appears to constitute the
main nucleolin binding region (NBR). However, as both the
HRDC+and C-terminal fragments extend N-terminal to residue
1236, we cannot rule out the possibility that the WRN region
1092–1236 might also participate in this interaction.
To verify this finding, GST-NCL fragments were mixed with
purified His6-WRN. These experiments clearly show that only the
C-terminal NCL domain, present only in the RGG and DN-NCL
fragments, binds WRNp (Figure 2D). The internal RBD 1–2 and
RBD 3–4 domains were unable to pull down WRNp in this assay.
To determine if WRNp interaction was through the NCL N-
terminal domain, we used a third fusion system. As the very acidic
NCL N-terminal end prevents efficient expression of full-length
nucleolin in the bacterial expression system, we produced GFP
fusion proteins in human cells. The GFP-NCL fusion constructs
were expressed in HeLa cells, and cell extracts were immunopre-
cipitated with anti-WRN. Only the construct containing the C-
terminal NCL domain, GFP-DN-NCL, was found to bind WRNp
(Figure 2E, right panel). These data, together with the data in
Figures 2A-D, indicate that the NCL N-terminal (residues 1 to
283) is not required for WRNp interaction and that the NCL
RGG domain is sufficient for optimal binding.
Camptothecin Induces Translocation of Nucleolin and
WRNp from the Nucleolus to the Nucleoplasm and the
Formation of Nuclear NCL-WRN Foci
Werner Syndrome cells (mutated Werner protein) are hyper-
sensitive to the Topoisomerase I inhibitor, camptothecin [41,42].
We have previously noted the remarkable effects of camptothecin
on nucleolar protein complexes [34]. When U2OS cells were
treated with camptothecin and several other DNA damaging
agents, we found that only in the presence of camptothecin did we
observe NCL (green) in the nucleoplasm (Figure 3A). Mitomycin
C, bleomycin, aphidicolin (not shown) and hydrogen peroxide (not
shown) did not redistribute nucleolin from the nucleolus to the
nucleoplasm, although all agents caused the Werner helicase (red)
to translocates from the nucleolus to the nucloplasm. Camptothe-
cin treatment results in the formation of numerous nuclear NCL
foci, some of which co-localized with WRNp foci in the
nucleoplasm (Figure 3A). That only a fraction of NCL and
WRN co-localize is not surprising, as both proteins interact with
many other proteins and participate in several protein complexes
at the same time.
Since WRNp and NCL were found to be in the same protein
complex in untreated cells and nuclear extracts (Figure 1 and
Figure S1), we examined the effect of DNA damaging agents on
the WRNp-NCL complex (Figure 3A and 3B). Whole-cell extracts,
prepared from U2OS cells that were treated with various DNA-
damaging agents, were precipitated with anti-NCL. In cells treated
with hydroxyurea (HU) or bleomycin only trace amounts of
WRNp were precipitated with NCL. In untreated control cell
lysates and in lysates from cells treated with CPT or 4NQO, more
WRNp was precipitated by anti-NCL (Figure 3B). Thus, there is
dissociation of immunoprecipitable WRN-NCL complexes in the
cells treated with HU and Bleomycin, but not in cells treated with
CPT, where some detectable WRN-NCL complexes remain.
These results confirm that the effects of CPT on the WRN-NCL
complex are specific and different from the other DNA damaging
agents examined.
We also investigated the timing of the CPT-induced trafficking
of NCL and WRNp using end-point immunofluorescence
experiments (Figure 3C). U2OS cells were treated with CPT,
washed and then fixed at time-points indicated. After treatment
with CPT, both WRNp (red) and NCL (green) have mostly
translocated from the nucleoli. At 2 hours post-treatment we
observed an increase of signal intensity of co-localizing WRN/
NCL (yellow) compared to the other time points, with numerous
small foci containing both proteins. By 8 hours post-treatment
both NCL and WRNp appear to have partially returned to the
nucleoli, with several large co-localizing foci remaining in the
nucloplasm. Full recovery of the pattern observed in non-treated
cells (co-localizing WRNp and NCL in nucleoli) occurs between 8
and 24 hours.
The half-life of camptothecin is 17 minutes at these incubation
conditions [43]. Thus, the original concentration of CPT is
reduced to less than 2% within 2 hours. Therefore, we would
expect to observe a more rapid response to CPT treatment than
was observed in the indirect immunofluorescence experiments. To
verify this possibility, we observed live U2OS cells that were
transfected with both GFP-NCL and RFP-WRN, and then treated
with 15 mM CPT (Figure 4, Movie S1). As can be seen in
Figures 4A and 4B, significant amounts of RFP-WRN and GFP-
NCL translocate from the nucleolus to the nucleoplasm in less
than 1 hour. Furthermore, these proteins co-localize in nuclear
foci after CPT treatment (Figures 4C and 4D), confirming the
indirect immunofluorescence experiments. We repeated these
experiments with a lower concentration of CPT, 1.0 mM (Figure
S2). We observe results similar to those obtained with the higher
CPT concentration of 15 mM. A dynamic proteomics analysis
showed a similar rapid nucleolar reduction of certain nucleolar
proteins, including nucleolin, after CPT treatment [44]. We also
observed that in approximately one half of the cells expressing
both GFP-NCL and RFP-WRN, nuclear foci can be clearly
observed (Table S1) with both proteins co-localizing. There was a
Figure 1. WRNp and NCL reciprocally co-immunoprecipitate.
Whole cell extracts were immunoprecipitated and immunoblotted as
described in Materials and Methods. Briefly, equal amounts of HeLa
extract were immunoprecipitated with rabbit anti-WRN (H300, Santa
Cruz, top panel), or rabbit anti-NCL (H250, Santa Cruz, lower panel).
Mouse antibodies were used to detect precipitated proteins and blots
were visualized with TrueBlot Western Blot kit. Control normal rabbit
IgG (IgG, Santa Cruz) was used as a negative control.
doi:10.1371/journal.pone.0035229.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e35229Figure 2. In vitro binding of WRNp and NCL. A-B. The WRNp binding domain of nucleolin is in the C-terminus. Indirect ELISA was performed as
described in Materials and Methods. Purified GST-nucleolin fragments (A) or purified His6-Werner proteins (B) were coated onto 96-well microtiter
plate wells. Coated protein was incubated with His6-Werner protein (A) or GST-nucleolin (B). Results shown were derived from a single plate, with
samples analyzed in quadruplicate and error bars showing the standard deviation from the mean. The co-efficient of variation was usually less than
10%. Experiments were replicated at least three times with similar results. See section D for nucleolin fragment names and mapping. BSA, plate
coated with only BSA; Ab, plate coated with only anti-WRN antibody. C. Different GST-WRN fragments were used to pull down nucleolin from nuclear
extract as described in the Materials and Methods section. Upper panel shows the detection of nucleolin only in the WRN fragments *HRDC+(amino
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treated with 15 mM CPT compared to 1.0 mM CPT (average of
63% vs. 43%, respectively).
Nucleolin Inhibits Werner Helicase Activity
As we have established the possibility of a physical interaction
between WRNp and NCL, we next examined whether NCL
affected the enzymatic activity of WRNp upon known WRN
substrates. The Werner protein is both a DNA helicase [22,23]
and exonuclease [24,29] and we examined the effect of adding
NCL to WRN activity assays. The helicase activity of WRN on a
22 base pair partial duplex fork substrate was efficiently inhibited
by NCL. Under the conditions used, 5 fmol WRN converted 80–
90% of the duplex (40 fmol) to single-strand form within 20
minutes at 37uC (Figure 5A). This conversion was inhibited by
about 50% when DN-NCL was present at a molar ratio of 25:1 vs
WRN. The RGG fragment, which contains the putative WRNp-
NCL interacting region (Figure 2), had an even greater inhibitory
effect on WRNp, with over 60% inhibition of helicase activity at a
10:1 ratio and 90% inhibition at 25:1 (Figure 5A). Other proteins
or NCL fragments, such as GST, RBD 1–2 and RBD 3–4 (not
shown), had no, or only minimal (about 20%) effect on WRN
unwinding of the duplex substrate at a molar ratio of 50:1.
In contrast, we observed that NCL had no effect on WRN
exonuclease activity upon a typical WRN substrate, a 39-recessed
DNA substrate (Figure 5B). To confirm the specificity of the NCL
interaction with the WRN helicase, we examined a non-RecQ
acid (a.a.) residues 1072–1432) and **C-terminal (a.a. residues 949–1432), but not in other fragments. NBR is the likely Nucleolin Binding Region of the
Werner protein. Membrane was stripped and immunoblotted with anti-GST antibody (lower panel). MW in kDa are indicated at right for each panel.
D. Different GST-nucleolin fragments were used to pull down full length purified His6-WRN. In the upper panel WRNp is present only in the nucleolin
fragments containing the RGG domain- RGG and DN-NCL. Same membrane was stripped and immunoblotted with GST antibody (lower panel). MW
in kDa are indicated at left for each panel. E. WRNp does not bind to NCL N-terminal domain. Constructs were transfected into HeLa cells, which were
extracted and immunoblotted as detailed in Materials and Methods. (A) Western Blot analysis of Nucleolin fragments from HeLa cells transiently
transfected with either pEGFP (lane 1), GFP-NCL 1–283 (N-terminal domain, lane 2) and GFP-NCL 284–707 (DN-NCL, lane 3). (B) Immunoprecipitation
with anti-WRN antibody of the above HeLa cell extracts, and detection with anti-GFP. Lanes as above. Only in lane 3 (GFP-DN-NCL) is a GFP signal
detected.
doi:10.1371/journal.pone.0035229.g002
Figure 3. Camptothecin induces translocation of nucleolin and Werner helicase. A. Confocal microscope images of WRNp (red) and NCL
(green) distribution after U2OS cells were treated with different DNA damaging agents as detailed in Materials and Methods. Fixed cells were stained
simultaneously with Rabbit anti-WRN (Novus) and Mouse anti-nucleolin (Santa Cruz). Note that WRNp re-localized from the nucleolus in all treatments
while nucleolin re-localized only after CPT treatment. Merged images show co-localization (yellow) of WRNp and NCL. Images are of representative
cells; At least 30 cells were analyzed for each treatment, which was repeated at least three times. B. Cells treated as above were immunoprecipitated
with anti-NCL and immunoblotted as described in the legend for Figure 1. Mito C- mitomycin C, HU- hydroxyurea, CPT- camptothecin, 4NQ0-4-
nitroquinoline-1-oxide, Control- untreated U2OS (WRN plus) cells; WRN cells- Ag11395 WS cells (abnormal WRN), Mo IgG- negative control mouse IgG
precipitate; Control input-10% of whole cell extract used for IP. C. U2OS cells were treated with 15 mM CPT for 12 h and then washed with complete
medium. Cells were fixed at times from start of treatment as indicated at the left of the images, and processed for confocal microscopy as detailed in
Materials and Methods.
doi:10.1371/journal.pone.0035229.g003
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excess of NCL or RGG over UvrD had comparatively little effect
(about 20%) on UvrD activity- see Fig. 5C. A similar concentra-
tion of NCL or RGG inhibited WRN helicase activity by 2-to 4-
fold (Figure 5A). As nucleolin had no effect on WRN exonuclease
activity, or on a non-RecQ helicase, this indicates that NCL has a
specific effect on the WRN helicase activity.
Nucleolin Inhibits Werner Helicase Activity on a G4
Tetraplex DNA Substrate
Most helicases of the RecQ family are able to unwind G4
tetraplex structures. We next sought to examine the effect of
nucleolin on WRN unwinding of G4 tetraplex DNA. Under the
conditions used, 5 fmol WRN converted 30–50% of the G4 DNA
(40 fmol) to single-strand form within 20 minutes at 37uC
(Figure 6, lanes 8 and 18). For comparison purposes, this
unwinding by WRNp was defined as ‘‘100% single-stranded’’, as
seen in Figure 6. As with the forked duplex substrate, the presence
of DN-NCL at a 25:1 ratio was sufficient to inhibit 80% (lane 10)
of this conversion and a similar ratio of RGG inhibited 60% of the
reaction (lane 17). Again, as with the duplex fork helicase
substrate, the presence of GST, RBD 1–2 and RBD 3–4 fragments
had little (less than 20%) or no effect on G4 DNA unwinding by
WRN.
Nucleolin and the NCL RGG Domain Bind G4 DNA
Utilizing electrophoretic mobility shift assays (EMSA), we
determined that WRNp, DN-NCL and the RGG domain could
Figure 4. GFP-NCL and RFP-WRN co-localize in the nucleoplasm after CPT treatment. U2OS cells were transfected with GFP-NCL (green)
and RFP-WRN (red) as described in Materials and Methods. Cells were treated with 15 mM CPT and immediately imaged in a time series obtained with
a Zeiss 710 confocal. A. Still images from a 120 minute time series at 0, 30 and 120 minutes after the addition of CPT. B. Still images from a 14 hour
time series at 0, 44 and 360 and 600 minutes after the addition of CPT. C. A 3x zoom on two cells from the 120 minute time series, comparing the
distribution of GFP-NCL and RFP-WRN at 0 and 30 minutes. Arrows point to co-localizing WRN-NCL foci (orange-yellow) in the nucleoplasm. D. A4 x
zoom on a cell from the overnight time series, comparing the distribution of GFP-NCL and RFP-WRN at 0, 44 and 360 minutes. Arrows point to co-
localizing WRN-NCL foci (orange-yellow) in the nucleoplasm. Note the intense co-localization of NCL and WRNp in the nucleoli at 0 min, and that
most of the WRNp and some of the NCL have translocated to the nucleoplasm within 30 (A) and 44 (B) minutes, where co-localizing NCL-WRN foci
can be already detected (C and D).
doi:10.1371/journal.pone.0035229.g004
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ATP converts the G4 form to single-strand DNA (Figure 6, lanes 8
and 18; Figure 7, lane 4). A high molecular weight (HMW) slowly-
migrating G4 DNA, interpreted as a WRN/G4 complex, can also
be seen in Figure 7, lane 4 and in all lanes where WRNp is
present. Increasing the amount of WRNp increases the WRN/G4
DNA complex signal in a dose-responsive manner (lanes 5–7). The
introduction of DN-NCL reduces the WRN-G4 DNA complex
signal (lanes 9–10), decreases the amount of free G4 DNA present
and introduces a new band, interpreted as DN-NCL-G4 DNA
complex, that can be seen also when WRN is not present (lane 8).
These data indicate that both WRNp and DN-NCL can bind G4
DNA when both proteins are present (lanes 9,10, 12–14) or when
only WRNp (lanes 4–7) or NCL (lanes 9–10) were added to the
substrate. When we add the RGG fragment instead of DN-NCL in
the absence of WRNp, a new band, interpreted as RGG-G4 DNA
complex appears (lane 11). Increasing the quantity of RGG
present reduces the WRN/G4 DNA signal in a dose-responsive
manner (lanes 12–14), indicating that RGG out-competes WRNp
for G4 DNA. It is also possible that RGG and WRNp bind G4
DNA and supershift it, resulting in the reduced G4-WRN signal of
lanes 13 and 14. Furthermore, increasing the amount of RGG
Figure 5. NCL inhibits WRN helicase activity but not WRN exonuclease activity. A. WRN unwinding of a helicase substrate, 22 base pair
partial duplex fork substrate (shown at left), was performed as described in Materials and Methods. Purified WRNp (5 fmol) was incubated with
40 fmol substrate and 50, 125, or 200 fmol of DN-NCL (lanes 12–15) or RGG fragment (lanes 5–8). Controls are GST protein (200 fmol, lane 10), RBD 3–
4 fragment (200 fmol, lane 9), W, only WRNp protein (lanes 4 and 11), B- only reaction buffer (lane 3), D- heat denatured substrate (lane 2), Oligo-
unreacted substrate (lane 1). In Lanes 5 and 13 the WRN protein was omitted from the reaction. Green circles point out the inhibitory effect of RGG
(lane 8) or DN-NCL (lane 15) on WRN helicase activity. B. WRN protein (100 fmol) was incubated with the exonuclease substrate (39-recessed DNA
substrate, represented at the top of the figure) in the presence of increasing amounts of DN-NCL (25, 50, 100, 200, 400 fmol) under exonuclease
reaction conditions for 1 h at 37uC, as described in Materials and Methods. Once the reactions were stopped, DNA products were resolved by
denaturing polyacrylamide gel electrophoresis. Controls are only reaction buffer (lane 1), only 400 fmol DN-NCL (lane 2), only WRN protein (lane 3)
and D- heat denatured substrate (lane 9). C. E. coli UvrD protein (10 fmol) was incubated with the Mix 4/3 substrate (represented to the right of the
figure) in the presence of increasing amounts of DN-NCL (100, 250, 400 fmol) under UvrD helicase reaction conditions for 1 h at 37uC, as described in
Materials and Methods. Once the reactions were stopped, DNA products were resolved by native polyacrylamide gel electrophoresis. Controls are
only reaction buffer (lane 1), WRN helicase (5 fmol, lane 2), 250 or 400 fmol DN-NCL without helicase (lane 10–11), RGG protein without helicase (lane
12–13) and D- heat denatured substrate (lane 14).
doi:10.1371/journal.pone.0035229.g005
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migrating position (lane 11) to a slower migrating one (lane 14),
possibly due to the increase in the number of RGG molecules
binding each G4 DNA molecule (G4-RGG(n)).
Discussion
These studies show that nucleolin is physically associated with
the Werner helicase in the nucleolus and nucleus. This conclusion
is based on the specific and reciprocal co-immunoprecipitation of
these proteins, in vitro binding assays and co-localization by
indirect immunofluorescence in confocal optical sections, and in
live cells transfected with both proteins. We have identified the C-
terminal domains of both proteins as the interacting regions, and
have determined that WRNp has a nucleolin binding domain,
probably in the region of aa residues 1236–1432. Furthermore,
treatment of cells with camptothecin causes the dissociation of
both nucleolin and WRNp from nucleolar complexes, followed by
their translocation to the nucleoplasm, where we find WRNp and
NCL in the same protein complexes. This dynamic process of
protein relocation from the nucleolus following DNA damage is
clearly seen in live cells transfected with GFP-NCL and RFP-
WRN. Our data further suggests that NCL and WRNp both
participate in complexes that include G4 tetraplex DNA.
Nucleolin co-localizes with WRNp in the nucleoli of untreated
cells. This nucleolar complex was dissociated by treatment with
the DNA-damaging agent, camptothecin. CPT is a DNA
topoisomerase I inhibitor that blocks topoisomerase I kinase
activity [45] and causes DNA strand breaks [46,47]. Cells and cell
lines derived from Werner Syndrome patients were shown to be
sensitive to the genotoxins camptothecin and 4-NQO [41,48,49].
We observed that other genotoxic agents, such as mitomycin C
and bleomycin did not dissociate nucleolin from the nucleolus as
did CPT. WRNp had increased nuclear signal after treatment with
bleomycin, mitomycin C and CPT, but only CPT increases
nuclear dispersion of nucleolin, while possibly retaining the
WRNp-nucleolin interaction. Similarly, topoisomerase I was
shown to dissociate from nucleoli after treatment with the CPT
Figure 6. NCL inhibits WRN unwinding of G4 tetraplex DNA.
The preparation of G4 tetraplex substrate was performed as described
in Materials and Methods. Purified WRNp (5 fmol) was incubated with
40 fmol G4 DNA substrate and 125 or 200 fmol DN-NCL (lanes 9–10) or
40, 125 or 200 fmol RGG fragment (lanes 15–17). Other lanes contain
controls-DN-only DN-NCL (40 fmol, lane 3), 1-1-RBD 1–2 fragment
(200 fmol, lanes 4, 11and 12), 3-4-RBD 3–4 fragment (200 fmol, lanes 5,
13 and 14), GST- GST protein (200 fmol, lane 19), Only WRN protein on
lanes 8 and 18, B-only reaction buffer (lane 2), D- heat denatured
substrate (lane 1). Reactions were terminated after 20 min at 37uC and
run out on 8% polyacrylamide gels. A representative intact gel is shown.
doi:10.1371/journal.pone.0035229.g006
Figure 7. NCL competes with WRN binding of G4 tetraplex DNA. Electrophoretic mobility shift assay (EMSA) was performed for the 49-mer
TP-G4 DNA with only WRNp (lanes 5–7:5, 10, 20 fmol) and 10 fmol WRNp in the presence of DN-NCL (lanes 9–10:25, 40 fmol) or RGG (lanes 12–14:25,
40, 80 fmol). Reactions were incubated for 20 min at 37uC and run out on 5% polyacrylamide gels at a cross-linker ration of 19:1 acrylamide:bis. Gels
were run at 6.5 V/cm for 4–6 h at room temperature. Control lanes: D- heat denatured substrate (lane 1); C, C’-only reaction buffer, at 4uC (lane 2) or
37uC (lane 3); ATP-10 fmol WRNp plus ATP (all other lanes contain ATPcS); Lanes 8 and 11 contain only 25 fmol DN-NCL or RGG, no WRNp,
respectively. The position of the oligonucleotide or oligonucleotide-protein complex is indicated at the right. A representative intact gel is shown.
doi:10.1371/journal.pone.0035229.g007
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have previously shown that CPT dissociates nucleolar protein
complexes containing WRNp and topoisomerase I [51] and also
dissociates the interaction between WRNp and the AAA ATPase
VCP in the nucleolus [34]. It is possible that CPT dissociated
WRNp from the nucleolus, but not from nucleolin, and that
WRN-NCL translocate together to the nucleoplasm. However,
our immunofluorescence and fluorescent protein data (Figure 3C,
Figure 4 and Figure S2) argue against this. It is more likely that the
events unfold as seen in the live cell experiments- after CPT
treatment, both WRNp and NCL translocate to the nucleoplasm
and can subsequently form complexes seen as co-localizing foci.
In addition, we note that WRNp and NCL are co-precipitated
from nuclear extracts of non-treated cells and CPT-treated U2OS
cells, but not from CPT-hypersensitive Werner Syndrome cells or
from hydroxyurea or bleomycin treated U2OS cells. These
molecular data are consistent with the observation that CPT has
a specific effect on the survival of WS cells [19] when compared to
other DNA damaging agents, such as UV irradiation, hydroxy-
urea, bleomycin and alkylating agents [19]. These results
underline the complex nuclear protein trafficking that commences
after the cell is exposed to DNA damaging agents.
CPT not only increased the extra-nucleolar presence of WRNp
and nucleolin, but also induced the formation of multiple
nucleoplasmic foci where WRNp and nucleolin co-localize. This
interaction can be detected within 30 minutes after CPT treatment
and the number of nuclear complexes peaks at 2–4 hours after
CPT treatment and are largely gone from the nucleus after 8–24
hours of recovery, indicating that the WRNp/NCL foci are
consistent with CPT-induced damage repair complexes. We
should caution that this timeline is tentative, as some variability
in cell response to CPT has been observed and that the details
require further investigation.
The translocation of WRNp after treatment with topoisomerase
I inhibitors has been observed previously with other WRNp-
associated proteins. CPT induced WRNp translocation to
intranuclear repair foci that included the repair proteins Rad50
and RPA [52]. Nucleolin was found to inhibit replication in
response to stress conditions by binding RPA [53]. Interestingly,
heat-shock also translocates nucleolin to the nucleoplasm, where it
binds RPA for about two hours after treatment [13] and inhibits
DNA replication initiation [54]. WRNp also translocated from the
nucleolus to the nucleoplasm after treatment with the genotoxic
agent 4NQO [26] and under serum starvation [55]. Thus, certain
kinds of damage (CPT-induced DNA breaks, for example), prompt
the release from the nucleolus of many proteins involved in DNA
repair.
G4 tetraplex structures are found in rDNA, telomeric DNA and
IgG DNA, regions that have abundant nucleolin [56,57]. These
complex structures are unwound in vitro by the RecQ helicase
family members BLM, WRNp and Sgs1p [40,58,59]. Nucleolin
can also bind to G4 DNA with a kD=0.4 nM [60], and is known
to promote the formation of c-MYC G4 DNA ([61]). Indeed, we
can see in our results that nucleolin efficiently prevents the
unwinding of G4 DNA by WRNp. WRNp probably binds G4
DNA via its RQC domain, similar to BLM and Sgs1p [62], and
binds the NCL C-terminal to the HDRC region (between residues
1236–1432), where we have located the nucleolin-binding region
of WRNp. Our EMSA results indicate that both WRNp and NCL
bind to G4 DNA, and that the RGG fragment of nucleolin shows
a high affinity to G4 DNA. Indeed, increasing RGG amounts
seem to reduce WRNp bound to G4 DNA, while increasing
amounts of nucleolin does not seem to have that effect. As
nucleolin appears to utilize its RGG region in order to bind both
G4 DNA and WRNp, the nucleolin-G4 DNA interaction is
perhaps stronger than the NCL-WRNp interaction, and that is
why nucleolin is unable to dislodge WRNp as can RGG. These
observations indicate a possible competitive mechanism for the
regulation of WRNp function by nucleolin: NCL binding to the
WRN nucleolar binding region might prevent WRN helicase
activity; subsequently, when the NCL-WRN complex is dissoci-
ated, for example, by NCL binding to a preferred substrate such as
G4 DNA, WRN helicase function is released from inhibition.
What sense can we make of the nucleolar to nucleoplasm
trafficking of these proteins in response to genomic stress? The
nucleolus was found to contain over 500 proteins [63], many of
which are unconnected to nucleic acid metabolism or processing
[9]. In response to several types of stress, the nucleolus is
depopulated of proteins, and there is a sharp increase in the
amount of these proteins in the nucleoplasm, as we have noted for
WRNp and NCL. We have previously suggested that the nucleolus
serves as a convenient depot for many proteins involved in the
response to DNA damage [34,64]. DNA damage activates these
quiescent proteins, perhaps via phosphorylation, and the nucleolar
complexes are rapidly disassociated, perhaps by VCP in an ATP
dependent process. In support of this scenario we note that both
WRNp and VCP are tyrosine phosphorylated in the nucleolus
after hydrogen peroxide treatment [26,65].
Rapid nucleolar protein complex dissociation after DNA
damage from CPT, for example, and dispersal to the nucleoplasm,
enables DNA damage response proteins such as WRNp and
nucleolin to greatly and rapidly increase in the nucleoplasm, where
they can be engaged in the formation of DNA repair foci in the
proper hierarchical sequence. We propose that nucleolin may
inhibit WRNp action in the nucleoplasm until it is required in the
DNA repair event. Thus, we find new WRNp-nucleolin complexes
(Figure 4 and Figure S2) or WRNp-topoisomerase complexes in
the nucleoplasm [51]. The relocation mechanism is a specific
response to CPT-induced stress. For example, in cells treated with
actinomycin D, both NCL (C23) and Nucleophosmin (B23)
remain in the nucleolus, while DNA helicase II left the nucleolus
[66,67]. Therefore, the specific effects on WRN and NCL caused
by CPT induced damage (DNA breaks), in which NCL and WRN
translocate from the nucleolus to the nucleoplasm and subse-
quently interact, is neither seen after transcriptional perturbation
(Actinomycin D), nor after inhibition of DNA synthesis (HU). We
have shown three lines of evidence that the WRN helicase and
nucleolin interact: reciprocal immunoprecipitation, immunofluo-
rescent co-localization and in vitro binding of purified proteins.
Furthermore, our results indicate that this interaction is probably
via their C-termini. In addition, we have examined the possible
role of NCL on WRN function utilizing WRN in vitro functional
assays. We show that NCL can inhibit the WRN helicase, but not
exonuclease function, and that they may co-regulate G4 DNA
unwinding in the response to certain DNA damaging agents such
as CPT. We have postulated that the NCL-WRNp complex may
be the inactive form of WRNp that is released from the nucleolus.
After increasing in the nucleoplasm and reaching a critical mass,
WRNp is released from inhibition and can participate in the DNA
repair processes at the required time and sequence. The precise
specificity and timing of this response to DNA damage will be the
focus of our future research.
Supporting Information
Figure S1 WRNp and NCL reciprocally co-immunopre-
cipitate. Nuclear extracts (A) or whole cell lysates (B) were
immunoprecipitated and immunoblotted as described in Materials
Nucleolin Inhibits Werner Helicase Activity
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e35229and Methods. A. Equal amounts of TERT-1604 nuclear extract
were immunoprecipitated with anti-NCL mAb (lanes 1 and 7-
CalBiochem), or goat anti-WRN (lanes 2 and 8). Rabbit anti-
WRN (lanes 1 4) or rabbit anti-NCL (lanes 5 9) were used to
detect precipitated proteins and blots were visualized by enhanced
chemiluminescence. Control Rabbit IgG (rb IgG, Sigma) precip-
itates are shown in lanes 4 and 9. Lys-Nuclear pellet proteins
extracted by Triton X-100 solubilization (lanes 3 and 5); Pellet-
Triton6-100 insoluble fraction (lane 6). MW in kDa are indicated
at left. B. Cells as indicated were solubilized with Nonidet NP-40
and equal amounts of lysates were immunoprecipitated with rabbit
anti-WRN. Mouse anti-WRN (top) or mouse anti-NCL (bottom)
were used to detect precipitated proteins and blots were visualized
by enhanced chemiluminescence. AG11395 is a Werner Syn-
drome cell line that contains abnormal WRNp, which is not
precipitated by the anti-WRN. WB- Western blot; IP- immuno-
precipitation.
(TIF)
Figure S2 GFP-NCL and RFP-WRN co-localize in the
nucleoplasm after 1.0 mM CPT treatment. U2OS cells were
transfected with GFP-NCL (green) and RFP-WRN (red) as
described in Materials and Methods. Cells were treated with
1.0 mM CPT and immediately imaged in a time series obtained
with a Zeiss 710 confocal. Still images from a 120 minute time
series at 0, 3, 10 and 114 minutes after the addition of CPT. An
enlarged image of the same nucleoplasmic foci is shown below
each frame, illustrating the dynamic nature of the interaction.
(TIF)
Table S1 U2OS cells were transfected as described in Materials
and Methods and treated with either 1.0 or 15.0 mM CPT, and
images were collected as time series of a single field of cells or
multiple fields using the Tile function of the Zeiss Zen software.
Double-transfected cells were examined for the appearance of
nuclear foci containing both NCL (green) and WRN (red). These
cells were counted as ‘‘Nuclear Foci Coloc.’’, in which foci are
non-nucleolar foci in which co-localization was observed in CPT-
treated nuclei.
(DOC)
Movie S1 GFP-NCL and RFP-WRN co-localize in the
nucleoplasm after CPT treatment. A movie of the 240
minute time series of images captured after addition of 15 mM
CPT to U2OS cells that were previously transfected with NCL
and WRN. Time series was converted with Zen software (Zeiss) to
AVI format at 6 fps. Each frame represents 2 minutes. The still
images in Figure 4A and 4C were taken from this series.
(AVI)
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